InterMune's development program for pirfenidone, IPF to be presented at Annual Congress of ERS

InterMune, Inc. (Nasdaq: ITMN) today announced that four oral presentations related to the company's development program for pirfenidone and idiopathic pulmonary fibrosis (IPF) will be presented at the Annual Congress of the European Respiratory Society (ERS), to be held September 18-22 in Barcelona, Spain.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased that our pirfenidone program will be the subject of three oral presentations at this year's ERS meeting. A fourth oral presentation will focus on Percent Predicted Forced Vital Capacity (FVC), a measure of clinical status in patients with IPF and the primary endpoint in our Phase 3 CAPACITY studies. We look forward to the presentation of these results and analyses at ERS."

The schedule of presentations at ERS related to InterMune's efforts in the development of new medicines for IPF is as follows:

Sunday, September 19, 10:45 a.m. – 12:45 p.m. (New Insights in the Treatment of IPF)

Geneva Room (Hall 1)

• 11:00 a.m. -- Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis: A comprehensive analysis of outcomes in CAPACITY 2 (Ulrich Costabel, M.D.)
• 11:15 a.m. -- The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis: A pooled analysis of outcomes in the CAPACITY trials (Carlo Albera, M.D.)
• 11:45 a.m. -- The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis: Analysis of outcomes in the CAPACITY trials (Dominique Valeyre, M.D.)

Tuesday, September 21, 8:30 - 10:30 a.m. (Clinical Issues in IPF)

Florence Room (Hall 1)

• 10:00 a.m. -- Percent predicted forced vital capacity is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (Ron du Bois, M.D.)

SOURCE InterMune, Inc.